

A CASE OF ANAPLASTIC THYROID CARCINOMA

ANGELLE KING, MS¹, CAMERON HENRY, MD², DORA CHEN, MD²

¹TULANE UNIVERSITY SCHOOL OF MEDICINE

²VANDERBILT UNIVERSITY MEDICAL CENTER




CLINICAL PRESENTATION

- 65-YEAR-OLD MAN WITH HYPERTENSION AND HYPOTHYROIDISM PRESENTED TO THE ED FOR A RAPIDLY ENLARGING NECK MASS, HOARSENESS AND INCREASING DYSPHAGIA OVER TWO MONTHS.
- PHYSICAL EXAM: NOTABLE FOR A LARGE ANTERIOR NECK MASS
- LABS: UNREMARKABLE, INCLUDING TSH


IMAGING – CT

- NECK CT REVEALED A CENTRALLY NECROTIC, ILL-DEFINED MASS MEASURING **3CM X 2CM X 6CM** IN THE RIGHT POSTERIOR THYROID CARILAGE EXTENDING TO THE ADJACENT RIGHT THYROID LOBE AND LYMPH NODES.
- CHEST CT REVEALED NUMEROUS BILATERAL PULMONARY NODULES AND PROMINENT MEDIASTINAL AND CERVICAL LYMPH NODES.




IMAGING – ULTRASOUND


- THYROID ULTRASOUND WITH FINE NEEDLE ASPIRATION (FNA) SHOWED A LARGE HETEROGENEOUS MASS TAKING UP A LARGE PORTION OF THE RIGHT INTERNAL JUGULAR VEIN (FIG A) AND MOST OF THE RIGHT AND LEFT THYROID GLAND (FIG B & C) WITH MULTIPLE PUNCTATE CALCIFICATIONS AND ONE LARGE CALCIFICATION IN THE UPPER POLE OF THE RIGHT THYROID GLAND.
- FNA PATHOLOGY RESULTS SHOWED ATYPICAL CELLS CONSISTENT WITH ANAPLASTIC THYROID CARCINOMA (ATC).



Transverse Right
Internal Jugular Vein





Sagittal Left
Lateromedial Thyroid



Sagittal Right
Lateromedial Thyroid

IMAGING – PET/CT

- MRI AND TOTAL BODY PET/CT WERE PERFORMED FOR STAGING, REVEALING AN INFILTRATIVE MASS INVOLVING THE ENTIRE THYROID, PROXIMAL ESOPHAGUS, BILATERAL CAROTID SPACES, AND BILATERAL COMMON CAROTID ARTERIES AND CONFIRMING INVOLVEMENT OF ADJACENT LYMPH NODES WITH NUMEROUS BILATERAL PULMONARY METASTASES.



MANAGEMENT

- ONCOLOGY, WITH INPUT FROM THORACIC SURGERY AND ENT, DETERMINED THAT THE MASS WAS UNRESECTABLE DUE TO SIZE OF THE LESION, INVASION OF ADJACENT STRUCTURES, AND ADVANCED METASTASES.
- RADIATION THERAPY AND ADJUVANT CHEMOTHERAPY WERE INITIATED TO REDUCE TUMOR BURDEN AND RELIEVE THE PATIENT'S SYMPTOMS

OUTCOME

- DESPITE UNDERGOING 10 ROUNDS OF RADIATION AND SEVERAL MONTHS OF CHEMOTHERAPY, THE PATIENT WAS PLACED ON HOME HOSPICE 6 MONTHS AFTER HIS DIAGNOSIS AND PASSED AWAY ONE WEEK LATER.

TAKE HOME POINTS

- ATC IS A RARE, BUT RAPIDLY PROGRESSIVE AND LOCALLY AGGRESSIVE MALIGNANCY WITH EARLY METASTASIS THAT REPRESENTS 1-2% OF THYROID CANCERS IN THE UNITED STATES BUT IS RESPONSIBLE FOR NEARLY 50% OF ALL THYROID CANCER-RELATED DEATHS.
- PATIENTS ARE TYPICALLY OVER THE AGE OF 60 AND PRESENT WITHIN WEEKS OF EXPERIENCING DYSPHAGIA AND AN ENLARGING NECK MASS.
- GOLD STANDARD FOR DIAGNOSIS IS ULTRASOUND-GUIDED FNA OR CORE BIOPSY.
- MANAGEMENT INCLUDES TOTAL THYROIDECTOMY WITH LYMPH NODE RESECTION, ADJUVANT RADIATION THERAPY, AND CHEMOTHERAPY. DUE TO THE HIGH LIKELIHOOD OF DISTANT METASTASES AT THE TIME OF DIAGNOSIS, STAGING WORK-UP IS EXTENSIVE, INVOLVING PET/CT OF THE WHOLE BODY AND MRI OF THE BRAIN.
- IMAGING ALSO HELPS GUIDE SURGICAL MANAGEMENT, WITH EVIDENCE OF CAROTID ENCASEMENT, SUCH AS IN THIS CASE, MAKING THE TUMOR INOPERABLE

REFERENCES

1. BIBLE KC, KEBEBEW E, BRIERLEY J, BRITO JP, CABANILLAS ME, CLARK TJ JR, DI CRISTOFANO A, FOOTE R, GIORDANO T, KASPERBAUER J, NEWBOLD K, NIKIFOROV YE, RANDOLPH G, ROSENTHAL MS, SAWKA AM, SHAH M, SHAHA A, SMALLRIDGE R, WONG-CLARK CK. 2021 AMERICAN THYROID ASSOCIATION GUIDELINES FOR MANAGEMENT OF PATIENTS WITH ANAPLASTIC THYROID CANCER. THYROID. 2021 MAR;31(3):337-386. doi: 10.1089/THY.2020.0944. ERRATUM IN: THYROID. 2021 OCT;31(10):1606-1607. doi: 10.1089/THY.2020.0944.CORREX. PMID: 33728999; PMCID: PMC8349723.
2. CALIFANO I, SMULEVER A, JERKOVICH F, PITOIA F. ADVANCES IN THE MANAGEMENT OF ANAPLASTIC THYROID CARCINOMA: TRANSFORMING A LIFE-THREATENING CONDITION INTO A POTENTIALLY TREATABLE DISEASE. REV ENDOCR METAB DISORD. 2024 FEB;25(1):123-147. doi: 10.1007/s11154-023-09833-1. EPUB 2023 AUG 31. PMID: 37648897.
3. JANNIN A, ESCANDE A, AL GHUZLAN A, BLANCHARD P, HARTL D, CHEVALIER B, DESCHAMPS F, LAMARTINA L, LACROIX L, DUPUY C, BAUDIN E, DO CAO C, HADOUX J. ANAPLASTIC THYROID CARCINOMA: AN UPDATE. CANCERS (BASEL). 2022 FEB 19;14(4):1061. doi: 10.3390/CANCERS14041061. PMID: 35205809; PMCID: PMC8869821.
4. MENON G, KASHYAP S, NAING PT, ET AL. ANAPLASTIC THYROID CANCER. [UPDATED 2024 OCT 29]. IN: STATPEARLS [INTERNET]. TREASURE ISLAND (FL): STATPEARLS PUBLISHING; 2025 JAN-. AVAILABLE FROM: [HTTPS://WWW.NCBI.NLM.NIH.GOV/BOOKS/NBK538179/](https://www.ncbi.nlm.nih.gov/books/NBK538179/)
5. MOLINARO E, ROMEI C, BIAGINI A, SABINI E, AGATE L, MAZZEO S, MATERAZZI G, SELLARI-FRANCESCHINI S, RIBECHINI A, TORREGROSSA L, BASOLO F, VITTI P, ELISEI R. ANAPLASTIC THYROID CARCINOMA: FROM CLINICOPATHOLOGY TO GENETICS AND ADVANCED THERAPIES. NAT REV ENDOCRINOL. 2017 NOV;13(11):644-660. doi: 10.1038/NRENDO.2017.76. EPUB 2017 JUL 14. PMID: 28707679.
6. WU SS, LAMARRE ED, YALAMANCHALI A, BRAUER PR, HONG H, REDDY CA, YILMAZ E, WOODY N, KU JA, PRENDES B, BURKEY B, NASR C, SKUGOR M, HEIDEN K, CHUTE DJ, KNAUF JA, CAMPBELL SR, KOYFMAN SA, GEIGER JL, SCHARPF J. ASSOCIATION OF TREATMENT STRATEGIES AND TUMOR CHARACTERISTICS WITH OVERALL SURVIVAL AMONG PATIENTS WITH ANAPLASTIC THYROID CANCER: A SINGLE-INSTITUTION 21-YEAR EXPERIENCE. JAMA OTOLARYNGOL HEAD NECK SURG. 2023 APR 1;149(4):300-309. doi: 10.1001/JAMAOTO.2022.5045. PMID: 36757708; PMCID: PMC9912167.